Zilun Hu

This inventor holds 26 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 11 EPO patents, primarily in Factor Xa Inhibitors. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zilun Hu. Retrieved from https://idiyas.com/inventor/zilun-hu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 11 (Patent Applications = 12)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 148(Granted Patents)

Location History:

Thornton, PA (US) (2006 - 2009)
Jamison, PA (US) (2007 - 2021)

Company Filing History:

26 out of 3,745

Bristol-Myers Squibb Compnay

patents

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

Factor XIa Inhibitors

Factor Xa Inhibitors

Macrocycles

Phenylpyrazole Derivatives

Tricyclic Pyrido-Carboxamide

Lactam Derivatives

Cyclic Urea

ROCK Inhibitors

Sulfonylaminovalerolactams

Arylpropionamide

Glycinamides

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12404274 - Macrocycles as factor xia inhibitors (2025-09-02),

2. 11136327 - Macrocycles as factor XIA inhibitors (2021-10-05),

3. 10730858 - Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors (2020-08-04),

4. 10487086 - Macrocycles as factor XIa inhibitors (2019-11-26),

5. 10112939 - Tied-back benzamide derivatives as potent rock inhibitors (2018-10-30),

6. 10081623 - Diamide macrocycles that are FXIa inhibitors (2018-09-25),

7. 9914740 - Tricyclic pyrido-carboxamide derivatives as rock inhibitors (2018-03-13),

8. 9902702 - Spirocycloheptanes as inhibitors of rock (2018-02-27),

9. 9828345 - Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors (2017-11-28),

10. 9802939 - Macrocycles as factor XIa inhibitors (2017-10-31),

11. 9663529 - Tricyclic pyrido-carboxamide derivatives as rock inhibitors (2017-05-30),

12. 9458110 - Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors (2016-10-04),

13. 9126944 - Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors (2015-09-08),

14. 8940720 - Macrocycles as factor XIa inhibitors (2015-01-27),

15. 8604056 - Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors (2013-12-10),

Title: The Innovative Contributions of Zilun Hu in Pharmaceuticals

Introduction

Zilun Hu is an accomplished inventor based in Jamison, Pennsylvania, with an impressive portfolio of 25 patents. His work primarily focuses on developing innovative pharmaceutical compounds that target crucial biochemical processes. He is currently affiliated with Bristol Myers Squibb Company, a leader in biopharmaceutical innovation.

Latest Patents

Among Zilun Hu's latest inventions are two notable patents with significant therapeutic implications:

1. **Macrocycles as Factor XIa Inhibitors**

This invention provides compounds of Formula (I) or its stereoisomers, tautomers, or pharmaceutically acceptable salts. These compounds serve as selective Factor XIa inhibitors or as dual inhibitors of Factor XIa and plasma kallikrein. The invention also includes pharmaceutical compositions that leverage these compounds, aiming to treat thromboembolic and inflammatory disorders effectively.

2. **Lactam, Cyclic Urea and Carbamate, and Triazolone Derivatives as Potent and Selective ROCK Inhibitors**

This patent presents compounds of Formula (I) or their stereoisomers, tautomers, or pharmaceutically acceptable salts. The focus is on these compounds as selective ROCK inhibitors. This innovation also encompasses pharmaceutical compositions intended to treat a range of conditions, including cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and inflammatory disorders.

Career Highlights

Throughout his career at Bristol Myers Squibb Company, Zilun Hu has demonstrated exceptional skill in translating scientific research into practical applications that address significant medical needs. His inventive work has been fundamental in advancing the company’s mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Collaborations

Zilun collaborates closely with esteemed colleagues such as Mimi Lifen Quan and Joanne M Smallheer. These collaborations have undoubtedly contributed to the innovative success of his research endeavors, facilitating the development of breakthrough therapeutic solutions.

Conclusion

Zilun Hu stands out as a remarkable inventor whose work continues to shape the landscape of pharmaceutical innovation. With a dedication to advancing medical sciences through his patents, he exemplifies the spirit of ingenuity and collaboration in addressing critical health challenges. His contributions are sure to leave a lasting impact on the field and enhance patient outcomes in the future.

Profile summary based on public USPTO records.